SCHEMBL6152748

SCHEMBL6152748

COC(=O)C1=C(CCc2ccccc2CN2CCN(C(=O)OC(C)(C)C)CC2)NC(CC(=O)N2CCN(C3CC4CCC(C3)N4C)CC2)=C(C(=O)OC)C1c1c(Cl)cccc1Cl

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 4/20 0.34
TP53 P04637 2/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
LMNA P02545 2/20 0.33
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33
STS P08842 1/20 0.33
SETD7 Q8WTS6 1/20 0.33
MGLL Q99685 1/20 0.33
NPC1 O15118 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
VEGFA P15692 1/20 0.32
EGLN1 Q9GZT9 1/20 0.32
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6152865 0.94 MEN1 (0.36) GPR119ALDH1A1MAPTTP53MEN1
SCHEMBL7132284 0.91 LMNA (0.35) GPR119ALDH1A1MAPTTP53MEN1
SCHEMBL6152262 0.90 HCRTR1 (0.35) MAPTMEN1KMT2ALMNAMGLL
SCHEMBL6152139 0.87 CCR3 (0.35) ALDH1A1MEN1KMT2AMAPK1
SCHEMBL6943069 0.86 CCR3 (0.35) ALDH1A1MEN1KMT2AMAPK1
SCHEMBL6152669 0.86 ALDH1A1 (0.40) GPR119ALDH1A1MAPTTP53MEN1
SCHEMBL7493254 0.85 SIGMAR1 (0.41) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL6947171 0.84 CCR3 (0.34) ALDH1A1TP53MGLLMAPK1
SCHEMBL6153116 0.84 CCR3 (0.33) KMT2AMAPK1
SCHEMBL6154279 0.84 CCR3 (0.33) ALDH1A1MAPTTP53LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6653313-B2 For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders WARNER-LAMBERT COMPANY LLC 2003-11-25 US claimed
EP-1307449-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2003-05-07 EP claimed
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists KAWAMURA MITSUHIRO (US) 2002-10-31 US claimed
WO-2002012235-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2002-02-14 WO claimed
EP-1307449-B1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMA (JP) 2005-12-07 EP disclosed
US-6653313-B2 For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders WARNER-LAMBERT COMPANY LLC 2003-11-25 US disclosed
EP-1307449-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2003-05-07 EP disclosed
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists KAWAMURA MITSUHIRO (US) 2002-10-31 US disclosed
WO-2002012235-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists BDKRB1, BDKRB2, HRH4 GPR119 1794/4885ALDH1A1 1798/4885MAPT 4516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.